All In Biotech

Drug Trial Radar · NCT07874984

SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer

A Phase 2 Study of SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2027

Study completion Nov 2029

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer. The objective is to evaluate the safety and efficacy of SPGL008 combined with SSGJ-706 in participants with driver gene-negative advanced non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • SSGJ-706Biological

    SSGJ-706 is a bispecific antibody that targets both human PD-1 and PD-L1

  • SPGL008Biological

    SPGL008 is a dual-functional molecule that combines an anti-B7-H3 monoclonal antibody with IL-15Rα sushi / IL-15.

  • ChemotherapyDrug

    Chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events(AEs) assessed by NCI-CTCAE v6.0Time frame: 24 months
  2. Objective Response Rate(ORR)Time frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.